Caveolin-1在骨肉瘤中的表达及其意义

目的观察Caveolin—1在骨肉瘤中的分布和表达情况，分析Caveolin-1在骨肉瘤临床诊断、治疗及预后评价中的意义。方法采用免疫组织化学SP法检测39例骨肉瘤组和22例良性骨肿瘤中Caveolin-1的表达，镜下观察Caveolin-1在肿瘤组织中的分布，应用自动图像分析检测Caveolin-1的表达情况。结果Caveolin-1表达于所有标本的肿瘤微血管和小血管内皮上，Caveolin-1表达于大多数骨肉瘤的肿瘤细胞，定位于细胞膜和胞浆，但在良性骨肿瘤中表达很微弱。Caveolin-1阳性表达率在骨肉瘤组中为59．0％，在良性骨肿瘤中为18．2％，两组间具有显著性差异（P〈0．01），有统计学意义，表明Caveolin-1在骨肉瘤中高表达。Caveolin-1的表达与骨肉瘤肿瘤体积、病理分型和患者的性别无关（P〉0．05），与骨肉瘤的组织分化和是否转移有关（P〈0．05）。结论Caveolin-1在骨肉瘤中高表达原因不明，其可能是促进骨肉瘤发生发展的一个潜在因素，也可能作为骨肉瘤治疗的新靶点。     

风筝样皮瓣修复面部软组织缺损的临床应用

目的探讨风筝样皮瓣在面部软组织缺损修复中的应用效果。方法我科自2005年1月至2008年5月．对21例面部因外伤、体表肿瘤、黑痣、瘢痕等切除术后软组织缺损进行修复。将病变组织行圆形、梭形或椭圆形切除．于缺损的一侧设计、形成以皮瓣基底部皮下组织为蒂，或以皮瓣两侧皮下组织为蒂的“风筝”样皮瓣，皮瓣最大宽度小于或等于缺损直径，长度约为缺损直径的2．0—2．5倍，推进覆盖缺损部位。结果21例患者术后风筝样皮瓣全部成活。经1。12个月，皮瓣在色泽、形态和功能上均保持良好，修复效果显著。结论风筝样皮瓣修复面部软组织缺损，血运可靠．切口愈合后瘢痕不明显，术后效果好，方法简单．值得推广。     

成人包皮环套术中结扎强度与相关并发症的关系

目的：探讨成人包皮环套术后包皮水肿和内外板分离的主要病阂。方法：选择300例门诊患者,予以前瞻、对照性研究。随机分两组,一组为强结扎作用（弹力线＋大套环）,一组为弱结扎作用（普通丝线＋小套环）,观察两组术后包皮水肿和内外板分离的发生率。结果：强结扎作用组出现72例中度以上包皮水肿,17例内外板分离,弱结扎作用组出现37例中度以上包皮水肿,5例内外板分离,前组发病率高于后组,差别均有显著性意义。结论：结扎作用过强是导致成人包皮环套术后皮水肿和内外板分离的主要病因。控制好两个作用力结扎线弹力和套环张力,为伤口创造一个良好的张力环境是降低术后上述两个并发症的关键。     

胡桃夹现象的诊断和治疗(附7例报告)

目的：探讨胡桃夹现象（NCS）的临床诊断与治疗。方法：回顾性分析7例NCS患者临床资料,临床主要表现主要为反复发作镜下或肉眼血尿、膀胱镜下发现左输尿管口喷血尿,B超、静脉。肾盂造影、DSA、CT三维重建、MRA等显示腹主动脉与肠系膜上动脉夹角处左肾静脉受压明显,。肾静脉近端扩张。结果：7例患者均明确诊断,其中6例临床症状较重者采用左肾静脉下移手术治疗,术后临床症状消失、痊愈出院。术后6个月复查多普勒彩色超声及尿液检查均未见异常。1例6岁患儿在随访中。结论：NCS临床特点为左肾静脉高压,反复肉眼或镜下血尿。左。肾静脉下移与腔静脉端侧吻合术是治疗该病的有效方法。     

经下腹部微笑切口的耻骨后前列腺癌根治术

目的：探讨经下腹部弧形微笑切口进行耻骨后前列腺癌根治术的方法和效果。方法：采用中心定位于前列腺的弧形微笑切口,进行耻骨后前列腺癌根治术14例,观察手术时间、输血量,并进行长期随访。结果：该切口暴露良好,易于手术操作。患者随访1～40个月．无切口相关并发症。结论：下腹部弧形微笑切口进行耻骨后前列腺癌根治术,有利于暴露、减少出血,切口愈合好符合美学观点,值得临床推广应用。     

肾上皮样血管平滑肌脂肪瘤3例临床病理观察

目的：探讨肾上皮样血管平滑肌脂肪瘤（Angiomyolipoma,AML）的临床病理特征及鉴别诊断依据。方法：回顾性分析3例肾上皮样AML的临床和病理改变状况,以及组织形态及免疫标记物的表达特点。结果：3例术前影像学检查均考虑为肾癌,镜下肿瘤内均缺乏脂肪组织,可见特征性的血管结构以及上皮样肿瘤细胞围绕血管呈袖套样排列,免疫组织化学染色示肿瘤细胞HMB45或Melan-A弥漫阳性,SMA阳性表达不定。结论：肾上皮样AML是一种少见的具有恶性潜能的肿瘤,诊断中需要注意与肾细胞癌相鉴别。免疫组织化学染色是诊断肾上皮样AML的一项必不可少的技术手段。     

HCCR-2反义核酸对肝癌HepG2细胞的作用

Objective To investigate the effects of antisense recombinant euraryotic expression vector of HCCR-2 on the proliferation and apoptosis of HepG2. Methods The antisense recombinant eukaryotic expression vector of HCCR-2 was constructed. The vector was stably transfected to the HepG2 cells, and positive clones were selected by G418 (antiseuse vector group), pIRES2-EGFP vector was transfected into the HepG2 cells in the same way (pIRES2-EGFP group). The conditions of the nontransfected HepG2 cells were used as control (HepG2 group). Changes in cell growth curve, cell cycle, cell apoptosis and morphology of HepG2 cells after the transfec-tion were detected by MTT method, flow cytometry and transmission electron microscopy, respectively. All the data were analyzed by one-way ANOVA and chi-square test. Results The expression level of HCCR-2 mRNA was down-regulated to 0.39±0.04 in antisense vector group, and the expression level of HCCR-2 mRNA in pIRES2-EGFP group and HepG2 group were 0.62±0.06 and 0.72±0.03, respectively, with significant difference among the 3 groups (F=43.701, P<0.05). The apoptotic rate of HepG2 cells in antisense vector group, pIRES2-EGFP grop and HepG2 group were 13.30%, 2.51% and 2.07%, respectively, with significant difference among the 3 group (χ2=6.793, 8.721, P<0.05). The growth of HepG2 cells in antisense vector group was retarded, and was blocked in G0/G1 stage. Conclusions The HCCR-2 antisense recombinant eukaryotic expression vector can inhibit the mRNA expression of HCCR-2 and promote the apoptosis of cells. HCCR-2 may be involved in cell regulation and the proliferation of hepatocellular carcinoma cells.     

强化精氨酸肠内营养对烧伤患者营养状况和细胞免疫的影响

Objective To investigate the effects of arginine enriched enteral nutrition (EN) on nu-tritional status and cellular immunity of severely burned patients. Methods Randomized, single blind, parallel and positive control investigation was employed in the study. Thirty severely burned patients were di-vided into enteral immune nutrition (EIN) group and EN group. Sixteen patients in EIN group received en-teral nutrition enriched with arginine, while the other 14 patients in EN group received standard enteral nu-trition. Nutritional support was continued for 14 days. Gastrointestinal reaction of patients in 2 groups was observed. Fasting venous blood was drawn from patients of both groups before receiving nutrition treatment and on the morning of 7th, 14th day of treatment. Level of serum protein, hepatic function parameters, renal function parameters, fasting-blood glucose, and subpopulations of T lymphocytes in peripheral blood were determined. Results (1) Incidence of gastrointestinal side effect in EIN group (25.0%) was close to that of EN group (21.4% , P>0.05). (2) Compared with pre-treatment days, levels of prealbumin and transferrin in serum of patients in 2 groups on 7th and 14th post-treatment days were significantly increased (P<0.05 or P<0.01), but there was no significant difference between 2 groups. The level of total serum protein on 14th day of treatment of patients was significantly increased in both groups, and that of EIN group (66±7 g/L)was significantly higher compared with that in EN group (64 ± 11 g/L, P<0.05). The level of serum albumin (29±5, 32±5 g/L, respectively) of patients in EIN group on 7th and 14th day of treat-ment were significantly higher than that (26±4 g/L, P <0.05) in pre-treatment days, however there was no significant difference in EN group. (3) There was no significant difference in respect of hepatic function, renal function, and fasting-blood glucose between pre-treatment and post-treatment periods in both groups (P>0.05). (4) The ratio of CD4+ , CD8+ on 14th day of treatment in EIN group was close to that of pre-treatment level. In EN group, cell percentage of CD4+ significantly decreased, while that of CD8+ significantly increased (P<0.05), and CD4+ was significantly higher [(56±8) %] in EIN group than that in EN group [(55±12) % , P <0.05]. In both groups, cell percentage of CD3+ was significantly higher than that in pre-treatment days (P<0.05), while there was no obvious change in CD4+/CD8+. Conclusions Arginine enriched enteral nutrition can effectively improve nutritional status and cellular immune function of burn patients.     

Rosiglitazone down-regulates lipopolysaccharide-induced expression of CD40 and intercellular adhesion molecule 1 in rat peritoneal mesothelial cells through a NF-κB dependent mechanism

Objective To investigate the effect and mechanism by which PPARγ ligand, rosiglitasone, regulates the expression of CD40 and intercellular adhesion molecule 1 (ICAM-1) in the rat peritoneal mesothelial cells (RPMCs) induced by lipopolysaccharide (LPS). Methods RPMCs were harvested from Sprague-Dawley rat peritoneal cavity and maintained under defined in vitro conditions. The cells were randomly divided into groups as follows: medium, LPS (5 mg/L), LPS (5 mg/L)+BAY11-7085(5 μmol/L, NF-κB inhibitor), rosiglitazone (10 μmol/L or 20 μmol/L, peroxisome proliferator-activated receptor γ activator), LPS (5 mg/L)+rosiglitazone (10 μmol/L)+GW9662 (3 μmol/L, peroxisome proliferator-aetivatcd receptor γ antagonist), and LPS (5 mg/L)+vehicle (DMSO 0.2 ml/L). The expressions of CD40 and ICAM-1 RNA in RPMCs were examined by RT-PCR after 3 hour treatment, and the protein expressions of CD40, ICAM-1, p-NF-κB p65 and p-IκBα were examined by Western blot or immunofluorescence after 24 hour treatment. Results Following treatment with LPS, both the expressions of CD40 and ICAM-1 protein in RPMCs were up-regulated significantly (P<0.05), and the phosphoralation of p65 was increased greatly (1.10±0.17 vs 0.55±0.06, P<0.05). BAY11-7085 (5 μmol/L) significantly decreased the protein expression of p-p65 (0.22±0.11 vs 1.10±0.17, P<0.01), CD40 (0.34±0.02 vs 0.50±0.06, P<0.05) and ICAM-1 (0.35±0.16 vs 0.74±0.03, P<0.05). Pretreated with rosiglitazone for 3 h then added with LPS for 1 h, the levels of p-p65, CD40 and ICAM-1 in RPMCs were significantly decreased compared with those of LPS group (0.77±0.08 vs 0.90±0.10, P相似文献   

上唇短缩畸形的手术治疗

目的 针对微笑时鼻唇部出现上唇上提并短缩,鼻小柱下方褶沟,上唇牙龈外露等现象,探讨一种治疗上唇短缩畸形的手术方法.方法 采用经口或鼻前庭切口,将鼻小柱根部鼻中隔降肌肌纤维切断及部分切除,并广泛剥离使上唇下降.结果 共为27例上唇短缩畸形患者进行手术治疗.其中9例采用了双侧鼻小柱外侧与前庭基底贯穿切口,18例采用了上唇唇龈沟切口.通过手术,患者获得微笑时上唇中部适度降低,鼻小柱下方褶沟变浅或消失,上唇牙龈外露消失的效果.6例患者还在手术矫正上唇动态短缩畸形的同时,实施了鼻整形术.通过手术可矫正鼻唇牙龈部的综合动态缺陷,获得满意的美学效果.结论 手术方法治疗上唇短缩畸形,可改善患者微笑时的表情,是值得推广的治疗方法.